The Big Idea
Cholesterol has a public-relations problem. It gets talked about as if it were a poison sloshing through your bloodstream. It isn’t.
Every cell in your body needs cholesterol to build its outer wall. Your body uses it to make hormones such as estrogen and testosterone, vitamin D, and bile—the greenish fluid your liver sends into the gut to help digest fat.
The problem is not that cholesterol exists. The problem is how many of a specific kind of cholesterol-carrying particle—the kind that can enter and become trapped in artery walls—are traveling through your blood, and how long they stay there before your body clears them out. These are called atherogenic particles.
Because fat and cholesterol do not dissolve in blood, your body packages them into tiny vehicles called lipoproteins—bundles of fat and protein. Think of them as a city transit system: some vehicles run passenger routes carrying cholesterol from stop to stop, some run long-haul freight carrying triglycerides, and a cleanup fleet runs the reverse route home.
Each vehicle has a job, a route, and identifying tags on its surface that tell the body what it is and what to do with it. When there are too many atherogenic vehicles on the road for too many years, some enter the wall of your arteries and become trapped there. That slow buildup is called atherosclerosis. It is the process that quietly leads to heart attacks, strokes, and other vascular disease over decades.
That is the whole story in one paragraph.
The rest of this article—Part 1 of a three-part series—is a tour of the fleet, the tags on each vehicle, and how to read what is actually showing up on your lab report. Parts 2 and 3 will cover what food, exercise, medications, and supplements actually change about the traffic pattern.
The Six Vehicles
Each vehicle carries apolipoproteins on its surface—identifying tags that tell the body what the vehicle is, where it belongs, and what to do with it.
One tag, apoB, is especially useful because it marks nearly every particle capable of contributing to plaque.
Chylomicron — the local shuttle
The pickup out of the gut after a meal. Chylomicrons carry fat from what you just ate into circulation.
Intact chylomicrons are generally too large to enter artery walls. But their smaller leftovers, called chylomicron remnants, can contribute to plaque.
Main tag: apoB-48 — one per particle, the gut-made form of apoB.
Also carries: apoA-I, apoA-II, apoA-IV, apoA-V, apoC-II, apoC-III, and apoE.
VLDL — long-haul freight from the liver
VLDL carries triglycerides made or packaged by the liver to muscle and fat tissue.
As VLDL drops off triglycerides along its route, it shrinks into smaller, cholesterol-rich remnant particles. These remnants can enter artery walls. This is one reason persistently high triglycerides can matter for cardiovascular risk.
Main tag: apoB-100 — one per particle, the liver-made form of apoB.
Also carries: apoC-I, apoC-II, apoC-III, and apoE.
IDL — a VLDL at a fork in the road
IDL is a shrunken VLDL particle. It can return to the liver for clearance or continue along the route and become LDL.
Main tag: apoB-100
Also carries: apoC and apoE. ApoE acts in part as a “return to liver” signal.
LDL — the main passenger route for cholesterol
LDL carries cholesterol through the circulation to cells and tissues. It is the most common plaque-forming particle, but it is not the only one.
LDL, cholesterol-rich remnants, and Lp(a) can all enter and become retained in artery walls. LDL is usually the dominant source of this traffic.
Main tag: apoB-100 — one per particle. This is why an ApoB blood test is such a useful approximation of the number of LDL and other atherogenic vehicles in circulation.
HDL — the return route
HDL participates in moving cholesterol away from tissues and toward the liver.
Its role is biologically complex. A high HDL cholesterol number is not proof that a person is protected from cardiovascular disease, and medications that simply raise HDL cholesterol have not reliably prevented heart attacks or strokes.
Main tag: apoA-I — usually more than one per HDL particle and the defining protein of HDL.
Also carries: apoA-II, apoA-IV, apoC-I, apoC-II, apoC-III, and apoE.
Lp(a) — an LDL with an extra fitting
Lp(a), pronounced “L-P-little-a,” is an LDL-like particle with an extra protein attached to it.
Think of it as an LDL bus with an added piece bolted to the back. It carries cholesterol that can enter the artery wall, and its unusual structure may make it especially likely to promote plaque and clotting.
Lp(a) is largely inherited and usually remains fairly stable through adulthood. Most expert groups recommend measuring it at least once in adulthood because an elevated result changes how seriously the rest of the prevention plan should be taken.
Main tag: apoB-100 — the same one found on LDL.
Extra tag: apo(a) — attached to apoB-100 in a 1:1 ratio. Apo(a) helps explain why Lp(a) behaves differently from ordinary LDL.[^1][^2]
The Tag That Matters Most: ApoB
If you take one lab-report word away from this article, make it ApoB.
ApoB is the identifying protein carried by the particles most relevant to plaque: VLDL and its remnants, IDL, LDL, and Lp(a). Chylomicrons carry a related version of apoB, and their remnants can contribute too, but a routine ApoB test is mainly telling you about the atherogenic particles most people are worried about.
What the lab is measuring
Routine ApoB tests do not separately distinguish the liver-made apoB-100 from the gut-made apoB-48.
But under normal conditions—especially after fasting—nearly all of the ApoB measured in blood is apoB-100, the form found on VLDL, IDL, LDL, and Lp(a). That means the ApoB number on your report is, for practical purposes, a close estimate of the number of atherogenic particles most relevant to cardiovascular risk.[^3]
Two lab numbers that sound similar are measuring different things.
LDL cholesterol tells you how much cholesterol is being carried inside LDL vehicles.
ApoB tells you, more nearly, how many atherogenic vehicles are on the road.
A person can have an ordinary-looking LDL cholesterol value but still have a higher-than-expected apoB level because they have many cholesterol-poor LDL or remnant particles. This pattern is more common when triglycerides are elevated, insulin resistance is present, diabetes is present, or LDL-C and apoB do not agree with one another.
In those situations, apoB can provide a clearer estimate of atherogenic particle burden than LDL cholesterol alone.[^3][^4]
ApoB is not the whole risk picture. Blood pressure, diabetes, smoking, family history, chronic kidney disease, Lp(a), physical activity, diet, sleep, and—for selected patients—a coronary artery calcium scan all matter.
But ApoB is one of the most useful single numbers available, and many patients have never had it measured.
If ApoB is not available
Ask for non–HDL cholesterol.
Non–HDL cholesterol is simply total cholesterol minus HDL cholesterol. It measures the cholesterol carried in all of the major apoB-containing particles: VLDL, IDL, LDL, remnants, and Lp(a).
It is inexpensive, appears on nearly every standard lipid panel, and can be calculated from either a fasting or nonfasting sample. It often tracks well with ApoB and is especially useful when ApoB testing is unavailable, although it does not directly tell you the particle count.
The HDL fleet has its own major tag, called apoA-I. A high HDL cholesterol number can sound reassuring, but HDL biology is more complicated than “more is better.” High HDL-C alone is not proof that you are protected.
How to Read Your Lipid Panel
The most common reason a patient tells me their cholesterol is “fine” is that someone glanced at total cholesterol and said the word normal.
Total cholesterol is useful as a starting point, but it is rarely enough to guide a cardiovascular decision on its own. Here is what the report is actually telling you, line by line.
Total cholesterol
This is the sum of the cholesterol carried inside all lipoprotein particles, including LDL, HDL, VLDL, IDL, Lp(a), and remnant particles.
Because HDL cholesterol is included, total cholesterol can sometimes obscure the risk picture. A person with both high HDL-C and high LDL-C may have a total cholesterol level that does not immediately raise concern. Another person with low HDL-C and modest LDL-C may appear “borderline” on total cholesterol alone while having a relatively low apoB or non–HDL-C level.
Use total cholesterol as a starting glance, not as a decision by itself.
LDL cholesterol
LDL cholesterol is the cholesterol carried inside your LDL buses.
On many standard lipid panels, LDL-C is calculated rather than directly measured. Older reports often use the Friedewald equation. Newer Martin-Hopkins or Sampson/NIH equations are generally more accurate, especially when triglycerides are elevated or LDL-C is very low.
If triglycerides are above about 400 mg/dL, a fasting repeat panel is often helpful because the LDL calculation becomes less reliable. In that setting, non–HDL-C and ApoB can be especially useful.
LDL-C remains the number most guidelines are built around and the number many cholesterol medications are titrated against.[^5][^6]
HDL cholesterol
HDL cholesterol is the cholesterol carried inside the HDL cleanup fleet.
Higher HDL-C is associated with lower cardiovascular risk in large populations, but the relationship is not linear all the way up. Very high HDL-C is not necessarily better, and drugs that raise HDL-C have not reliably lowered heart attacks or strokes.
Think of HDL-C primarily as a risk marker and part of the overall metabolic picture—not as a number you should try to push upward with medication.
Triglycerides
Triglycerides are the main form of fat riding inside VLDL freight vehicles and, for a few hours after a meal, inside chylomicrons.
Elevated triglycerides can reflect insulin resistance, excess body weight, diabetes, refined-carbohydrate intake, excess alcohol, hypothyroidism, kidney disease, certain medications, or inherited lipid patterns.
Persistently elevated triglycerides often travel with more triglyceride-rich remnant particles in circulation, and those remnants can enter artery walls. Very high triglycerides also raise the risk of pancreatitis.
A fasting triglyceride below 150 mg/dL is generally considered normal, but the meaning of a result depends on the full metabolic and cardiovascular picture.
Non–HDL cholesterol
Non–HDL cholesterol is your total cholesterol minus your HDL cholesterol.
That one subtraction gives you the total cholesterol carried in all major atherogenic particles: VLDL, IDL, LDL, remnants, and Lp(a).
It is inexpensive, included on almost every standard lipid panel, and useful whether the blood sample was fasting or nonfasting. It often tracks well with ApoB and is especially valuable when ApoB testing is not available, although it does not directly measure particle number.
If ApoB is not available, non–HDL cholesterol is one of the most useful numbers to know.
ApoB
ApoB is not included on a standard lipid panel, so you usually have to ask for it.
It closely estimates the number of circulating atherogenic particles. It does not require fasting and is especially helpful when triglycerides are high, insulin resistance or diabetes is present, or LDL-C and non–HDL-C do not seem to tell the whole story.[^3][^4][^6]
Lp(a)
Lp(a) is not included on a standard lipid panel and must also be requested.
It should be measured at least once in adulthood because it is largely inherited and usually remains fairly stable.
In many expert statements:
Lp(a) below 30 mg/dL, or below 75 nmol/L, is considered lower risk
Lp(a) from 30 to 50 mg/dL, or 75 to 125 nmol/L, is considered an intermediate range
Lp(a) of 50 mg/dL or 125 nmol/L and above is considered high risk
Do not try to convert precisely between mg/dL and nmol/L. The two units are not interchangeable with one fixed formula because Lp(a) particle size varies substantially from person to person.
A high Lp(a) result does not mean disaster. It means your prevention plan—especially LDL-C and ApoB lowering—deserves more attention.[^1][^2][^7][^9]
Ratios
Total-cholesterol-to-HDL and LDL-to-HDL ratios are calculated automatically on many reports.
They can be useful for quick pattern recognition, but they can also hide important problems. A person can have a “great” ratio and still have a genuinely high ApoB or Lp(a).
Ratios are a supplement to the individual numbers, not a replacement for them.
A practical way to read the page
Start with LDL-C, non–HDL-C, and ApoB when it is available.
Then look at triglycerides. They can reveal whether triglyceride-rich lipoproteins and insulin resistance are contributing to the traffic pattern.
Then put all of it into the bigger cardiovascular picture: blood pressure, diabetes or prediabetes, smoking, kidney function, family history, Lp(a), age, sex, exercise, diet, sleep, and—when appropriate—coronary artery calcium.
Total cholesterol and HDL-C add useful context, but neither should dominate the interpretation.
Where Things Go Wrong
Most LDL buses are ultimately cleared by the liver.
The liver does this by putting docking ports on its surface that grab passing LDL particles and pull them in. These docking ports are called LDL receptors. Think of them as depot stations where the fleet gets pulled off the road for the night.
The more LDL-receptor stations the liver has open, the less time an LDL particle spends circulating in your blood. The less time it spends circulating, the less opportunity it has to enter and become trapped in an artery wall.
Anything that reduces the number of working depot stations—genetics, hypothyroidism, kidney disease, certain medications, and, for many people, a diet high in saturated fat—can leave more LDL particles sitting in traffic longer.
Anything that increases clearance—some dietary changes and most cholesterol-lowering medications—can reduce the time those particles spend circulating.
How strongly any individual person responds to these levers varies substantially.
What replaces saturated fat matters. Replacing it with unsaturated fats—such as olive oil, nuts, seeds, avocado, and many fish—usually lowers LDL-C more reliably than replacing it with refined carbohydrate.
Almost every cholesterol-lowering treatment works by pulling one of two levers:
Run fewer atherogenic vehicles
Open more LDL-receptor depot stations on the liver
That is the whole map.
What’s Next
You now have the map.
In Part 2, we will walk through what food and exercise actually change about the traffic pattern: which foods change which vehicles, why movement intensity matters, how body composition influences triglycerides and insulin resistance, and where the effects of lifestyle honestly sit next to the effects of medication.
In Part 3, we will cover the medications themselves and take an honest look at the supplements and herbals patients ask about most often—what each one does, what the evidence actually supports, and which ones are usually not worth the money.
Part 2 next Tuesday. Part 3 the Tuesday after.
This article is for patient education. It is not a substitute for individualized medical advice. Cholesterol management should be directed by your physician using validated risk assessment and current guideline-based therapy.
Key Sources
Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology. 2019;4(12):1287–1295.
Soffer DE, et al. Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus From the National Lipid Association. Journal of Clinical Lipidology. 2024.[^3][^8]
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Valve Stenosis: A European Atherosclerosis Society Consensus Statement. European Heart Journal. 2022.[^9]
National Lipid Association. A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice. 2024.[^1][^2]
Feingold KR. Guidelines for the Management of Dyslipidemia. Endotext [Internet]. 2026.[^5]
Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Circulation. 2026;153(17):e1154–e1276.[^4][^6]
[^1]: https://www.lipidjournal.com/article/S1933-2874(24)00033-3/fulltext
[^2]: https://www.lipid.org/resource/a-focused-update-to-the-2019-nla-scientific-statement-on-use-of-lipoproteina-in-clinical-practice/
[^3]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11734832/
[^4]: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423
[^5]: https://www.ncbi.nlm.nih.gov/books/NBK305897/
[^6]: https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia
[^7]: https://www.acc.org/latest-in-cardiology/articles/2023/09/19/10/54/an-update-on-lipoprotein-a
[^8]: https://www.lipidjournal.com/article/S1933-2874(24)00240-X/fulltext
[^9]: https://academic.oup.com/eurheartj/article/43/39/3925/6670882